GlassScriptPhysician profile
Sima Aman
NPI 1689396293
$3,531.02
in general payments reported to CMS, 2019-2025
18 companies · $894 in 2025
The $894 reported for 2025 was more than what 78% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $100 · 2023: $1,300 · 2024: $1,236 · 2025: $894.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,382 · Education: $48.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,381.78 |
| Education | $48.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $656.25 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $400.82 | 2023-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Alkermes, INC. | $382.18 | 2023-2025 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $281.12 | 2024-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Neurocrine Biosciences, INC. | $236.83 | 2023-2025 | Ingrezza |
| Lundbeck LLC | $220.17 | 2023-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $210.87 | 2023-2025 | Caplyta |
| Indivior INC. | $205.32 | 2023 | Perseris |
| Vanda Pharmaceuticals INC. | $199.03 | 2023-2025 | Fanapt, Hetlioz |
| Almatica Pharma LLC | $178.13 | 2023-2024 | Loreev Xr, Sertraline Hcl |
| Corium, LLC | $112.92 | 2023-2025 | Azstarys |
| Axsome Therapeutics, INC. | $112.33 | 2023-2025 | Auvelity |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $100.40 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $70.28 | 2023-2024 | Uzedy |
| Supernus Pharmaceuticals, INC. | $58.74 | 2024-2025 | Qelbree |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $55.97 | 2025 | Cobenfy |
| Tris Pharma INC | $33.73 | 2025 | Dyanavel Xr |
| Neuronetics, INC. | $15.93 | 2023 | Neurostar Tms Therapy System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sima Aman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.